Özçelik, EmrahKalaycı, AhmetÇelik, BüşraAvcı, AçelyaAkyol, HasanKılıç, İrfan BakiGüzel, TürkanÇetin, MetinÖztürk, Merve TuzlakoğluÇalışkaner, Zihni OnurTombaz, MelikeYoleri, DilanKonu, ÖzlenKandilci, Ayten2023-03-012023-03-012022-10-0319326203http://hdl.handle.net/11693/111998DEK has a short isoform (DEK isoform-2; DEK2) that lacks amino acid residues between 49–82. The full-length DEK (DEK isoform-1; DEK1) is ubiquitously expressed and plays a role in different cellular processes but whether DEK2 is involved in these processes remains elusive. We stably overexpressed DEK2 in human bone marrow stromal cell line HS-27A, in which endogenous DEKs were intact or suppressed via short hairpin RNA (sh-RNA). We have found that contrary to ectopic DEK1, DEK2 locates in the nucleus and nucleolus, causes persistent үH2AX signal upon doxorubicin treatment, and couldn’t functionally compensate for the loss of DEK1. In addition, DEK2 overexpressing cells were more sensitive to doxorubicin than DEK1-cells. Expressions of DEK1 and DEK2 in cell lines and primary tumors exhibit tissue specificity. DEK1 is upregulated in cancers of the colon, liver, and lung compared to normal tissues while both DEK1 and DEK2 are downregulated in subsets of kidney, prostate, and thyroid carcinomas. Interestingly, only DEK2 was downregulated in a subset of breast tumors suggesting that DEK2 can be modulated differently than DEK1 in specific cancers. In summary, our findings show distinct expression patterns and subcellular location and suggest non-overlapping functions between the two DEK isoforms. © 2022 Ozçelik et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.EnglishAmino AcidsChromosomal ProteinsNon-HistoneDNA DamageDoxorubicinHumansOncogene ProteinsPoly-ADP-Ribose Binding ProteinsProtein IsoformsRNASmall InterferingArticle10.1371/journal.pone.0275476